96 filings
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
29 Apr 24
Other Events
10:05am
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Apr 24
Other Events
4:36pm
S-1
SHPH
Shuttle Pharmaceuticals Holdings Inc
IPO registration
5 Apr 24
5:06pm
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 Mar 24
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
9:00am
424B3
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 Mar 24
Prospectus supplement
6:07am
8-K
8wam2ie
5 Mar 24
Shuttle Pharmaceuticals to Present at About Shuttle Pharmaceuticals
9:00am
8-K
zx325e5 db2
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
8-K
w9bwe1sv 24k01ras
5 Feb 24
Entry into a Material Definitive Agreement
4:25pm
8-K
g7ems
8 Jan 24
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
9:05am
8-K
5mipoil9k8c7qyb
19 Dec 23
Submission of Matters to a Vote of Security Holders
5:10pm
8-K
kzt6mjzgas6pf1gnw
11 Dec 23
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
8-K
zyow6knvcfp0h
30 Nov 23
Other Events
9:00am
8-K
hm4sexjlzyv j2crwouc
14 Nov 23
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
12:00am
8-K
itiny9
30 Oct 23
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
5:14pm
ARS
hm8sce
20 Oct 23
Annual report to shareholders
4:15pm
8-K
16vkm2x0
10 Oct 23
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
9:00am
8-K
t29cubd fbhzo9xyp4m6
5 Oct 23
Entry into a Material Definitive Agreement
4:10pm